Pharmafile Logo
Pharmafocus logo
Advanced Search

eams

Showing 15 posts of 15 posts found.

img_4190-e1376666350337-web

MHRA gives OK to Bavencio for first-line maintenance of advanced bladder cancer via the Early Access to Medicines Scheme

September 3, 2020
Sales and Marketing Bavencio, MHRA, Merck, Pfizer, UK, eams, pharma

It has been revealed that Bavencio (avelumab), jointly developed by Merck KGaA and Pfizer, has been approved by the UK …

News
shutterstock_57369385

Refining the system: Improving patients’ access to medicine

September 25, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NCIE, drug access, eams, market access, pharma, pharmaceuticals

The MHRA and NICE have been slowly improving the ways that the UK’s patients access medicines, but now Brexit threatens …

Feature

MHRA accepts Roche’s Tecentriq into Early Access to Medicines scheme

January 25, 2017
Research and Development, Sales and Marketing MHRA, Roche, eams, tecentriq

Roche’s Tecentriq (atezolizumab) has scored another positive opinion, this time from the Medicines and Healthcare products Regulatory Agency (MHRA), which …

News
opdivo

UK lung cancer patients get early access to breakthrough BMS drug

February 5, 2016
Research and Development, Sales and Marketing Bristol-Myers Squibb, MHRA, NICE, eams, opdivo

UK lung cancer patients are to get access to Bristol Myers-Squibb’s Opdivo (nivolumab) through the Early Access to Medicines Scheme …

News
MHRA

Early UK access for AstraZeneca lung cancer drug

December 9, 2015
AstraZeneca, Early Access to Medicines Scheme, Tagrissa, eams, lung cancer, non small cell lung cancer, non-small cell lung cancer, osimertinib

UK patients will be among the first in Europe to have free access to AstraZeneca’s cancer drug osimertinib, after the …

News

Novartis’ new heart failure medicine recommended for EU approval

September 25, 2015
Medical Communications, Research and Development Entresto, Novartis, eams, heart failure

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Novartis’s heart failure medication Entresto …

News
AstraZeneca plaque

AstraZeneca lung cancer drug clears UK market access hurdle

September 4, 2015
Sales and Marketing AZD9291, AstraZeneca, Early Access to Medicines Scheme, MHRA, NSCLC, eams, lung cancer, non-small cell lung cancer

Follow @Pharmafocus

News
Entresto

Novartis heart failure drug available via EAMS

September 3, 2015
Sales and Marketing Early Access to Medicines Scheme, Entresto, LCZ696, MHRA, Novartis, eams, heart failure, sacubitril/valsartan

Novartis has won the investigational heart failure treatment LCZ696 (sacubitril valsartan) will be available in the UK under the Early …

News

Opdivo launched in the UK for skin cancer

July 2, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Early Access to Medicines Scheme, MHRA, eams, melanoma, opdivo, skin cancer

Bristol-Myers Squibb has launched its cancer immunotherapy treatment Opdivo in the UK for patients with advanced skin cancer. Opdivo (nivolumab) …

News

BMS’ Opdivo accepted to UK early access scheme

June 30, 2015
Sales and Marketing BMS, Cancer, NSCLC, eams, keytruda, opdivo

Bristol-Myers Squibb has scored another first with its new-generation oncology therapy Opdivo, which has become the first lung cancer drug …

News
NICE image

NICE sets out office for market access plans

May 28, 2015
Sales and Marketing ABPI, EMA, NHS, NICE, eams, market access

The UK healthcare watchdog NICE is to set up a new office for market access to advise pharma companies on …

News
BMS image

BMS lifted by new products

April 28, 2015
Sales and Marketing BMS, NICE, Q1, eams, immuno-oncology and hepatitis C

New drugs have helped Bristol-Myers Squibb see a slight increase in sales for the first quarter of 2015. Total revenues …

News
Novartis image

Novartis heart drug steps closer to EAMS scheme

April 23, 2015
Sales and Marketing LCZ696, MHRA, Medicines and Healthcare products Regulatory Agency, NICE, eams, pim, sacubitril/valsartan

Novartis’ investigational heart failure drug LCZ696 has been handed a Promising Innovative Medicine designation (PIM) after showing that it significantly …

News

Novartis in major oncology drive

March 30, 2015
Research and Development, Sales and Marketing Cancer, FDA, MHRA, Novartis, aduro, ceritinib, eams, early access, zykadia

Novartis says it is ‘stepping up its efforts’ in cancer by launching major initiatives to discover new treatments to combat …

News
Keytruda image

Merck’s cancer drug sees first ever early access nod

March 11, 2015
Sales and Marketing Cancer, ICR, Merck, eams, early access, keytruda, melanoma, oncology, pembrolizumab

Merck’s skin cancer drug Keytruda has become the first drug to be approved through the new Early Access to Medicines …

News

Latest content

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023

Teva Pharmaceuticals shares phase 3 data for Ajovy as migraine treatment

December 6, 2023

British Medical Journal publishes letter calling on government to reduce rate of antidepressant prescribing

December 5, 2023

Genentech shares positive results from phase 3 trial for breast cancer treatment

December 5, 2023

Dr Stefano Gulià appointed as chief scientific officer of Kling Bio

December 5, 2023